Search research articles
Contact Us
Filters
Showing results (91-100 of 116) with videos related to
Page
of 12
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2011
Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study
Xavier García-Del-Muro, Antonio López-Pousa, Joan Maurel, et al.
JAMA Oncology
|
August 30, 2019
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial
Carlos Fernández-Martos, Carles Pericay, Ferran Losa, et al.
Lancet (London, England)
|
June 14, 2025
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial
Sheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, et al.
Clinical Sarcoma Research
|
July 1, 2016
Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study
Joan Maurel, Antonio López-Pousa, Silvia Calabuig, et al.
Scientific Reports
|
April 2, 2021
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab
Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Joan Maurel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 9, 2008
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F Sobrero, Joan Maurel, Louis Fehrenbacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2011
A combined strategy of SAGE and quantitative PCR Provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer
Enrique Casado, Victor Moreno García, Jose Javier Sánchez, et al.
Cancer Immunology, Immunotherapy : CII
|
September 9, 2022
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
Marta Español-Rego, Carlos Fernández-Martos, Elena Elez, et al.
Journal of the National Cancer Institute
|
July 5, 2023
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402
David Pesántez, Sanne Ten Hoorn, Isidro Machado, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2018
Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)
Joan Maurel, Santiago Sánchez-Cabús, Berta Laquente, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 116) with videos related to
Sort By:
Page
of 12
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
May 25, 2011
Randomized phase II study comparing gemcitabine plus dacarbazine versus dacarbazine alone in patients with previously treated soft tissue sarcoma: a Spanish Group for Research on Sarcomas study
Xavier García-Del-Muro, Antonio López-Pousa, Joan Maurel, et al.
JAMA Oncology
|
August 30, 2019
Effect of Aflibercept Plus Modified FOLFOX6 Induction Chemotherapy Before Standard Chemoradiotherapy and Surgery in Patients With High-Risk Rectal Adenocarcinoma: The GEMCAD 1402 Randomized Clinical Trial
Carlos Fernández-Martos, Carles Pericay, Ferran Losa, et al.
Lancet (London, England)
|
June 14, 2025
Retifanlimab with carboplatin and paclitaxel for locally recurrent or metastatic squamous cell carcinoma of the anal canal (POD1UM-303/InterAACT-2): a global, phase 3 randomised controlled trial
Sheela Rao, Emmanuelle Samalin-Scalzi, Ludovic Evesque, et al.
Clinical Sarcoma Research
|
July 1, 2016
Phosphorylated-insulin growth factor I receptor (p-IGF1R) and metalloproteinase-3 (MMP3) expression in advanced gastrointestinal stromal tumors (GIST). A GEIS 19 study
Joan Maurel, Antonio López-Pousa, Silvia Calabuig, et al.
Scientific Reports
|
April 2, 2021
Description of the genetic variants identified in a cohort of patients diagnosed with localized anal squamous cell carcinoma and treated with panitumumab
Lucía Trilla-Fuertes, Angelo Gámez-Pozo, Joan Maurel, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 9, 2008
EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer
Alberto F Sobrero, Joan Maurel, Louis Fehrenbacher, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 7, 2011
A combined strategy of SAGE and quantitative PCR Provides a 13-gene signature that predicts preoperative chemoradiotherapy response and outcome in rectal cancer
Enrique Casado, Victor Moreno García, Jose Javier Sánchez, et al.
Cancer Immunology, Immunotherapy : CII
|
September 9, 2022
A Phase I-II multicenter trial with Avelumab plus autologous dendritic cell vaccine in pre-treated mismatch repair-proficient (MSS) metastatic colorectal cancer patients; GEMCAD 1602 study
Marta Español-Rego, Carlos Fernández-Martos, Elena Elez, et al.
Journal of the National Cancer Institute
|
July 5, 2023
Total neoadjuvant therapy with or without aflibercept in rectal cancer: 3-year results of GEMCAD-1402
David Pesántez, Sanne Ten Hoorn, Isidro Machado, et al.
Cancer Chemotherapy and Pharmacology
|
September 19, 2018
Outcomes after neoadjuvant treatment with gemcitabine and erlotinib followed by gemcitabine-erlotinib and radiotherapy for resectable pancreatic cancer (GEMCAD 10-03 trial)
Joan Maurel, Santiago Sánchez-Cabús, Berta Laquente, et al.
Page
of 12